skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Phosphodiesterase-5 inhibitors in management of pulmonary hypertension: Safety, tolerability, and efficacy

Review

(1887) Views  (525) Full article downloads

Authors: Mitchell S Buckley, Robin L Staib, Laura M Wicks, et al

Published Date September 2010 Volume 2010:2 Pages 151 - 161
DOI: http://dx.doi.org/10.2147/DHPS.S6215

Mitchell S Buckley1, Robin L Staib1, Laura M Wicks1, Jeremy P Feldman2
1Department of Pharmacy, Banner Good Samaritan Medical Center, and 2Arizona Pulmonary Specialists Ltd, Phoenix, Arizona, USA

Abstract: Pulmonary arterial hypertension (PAH) is a progressive disease that causes severe disability and has no cure. Over the past 20 years, a variety of treatment options have evolved for the management of PAH. With an expanded therapeutic armamentarium come more complex decisions regarding treatment options. Agent selection depends upon several factors including efficacy, side effect profile, and cost, as well as convenience of administration. We have undertaken a review of phosphodiesterase-5 (PDE-5) inhibitors in PAH with a focus on efficacy and safety. A literature search was conducted using the Medline and Cochrane Central Register of Controlled Trials databases (1966–February 2010) for relevant randomized clinical studies. Overall, 10 studies met our inclusion criteria. Sildenafil was the most commonly studied agent, followed by tadalafil and vardenafil. Most trials found that the PDE-5 inhibitors significantly improved exercise capacity and lowered pulmonary pressures. However, there were conflicting results regarding these agents’ impact on improving cardiac function and functional class. Overall, these medications were effective and well tolerated with a relatively benign side effect profile. The PDE-5 inhibitors are an important option in treating PAH. While most of the published clinical data involved sildenafil, the other PDE-5 inhibitors show promise as well. Further studies are needed to determine the optimal doses of this therapeutic drug class, as well as its effects as adjunctive therapy with other agents in PAH.

Keywords: sildenafil, tadalafil, vardenafil, pulmonary hypertension






Readers of this article also read:

Preference for and adherence to oral phosphodiesterase-5 inhibitors in the treatment of erectile dysfunction
Patient preference and satisfaction in erectile dysfunction therapy: a comparison of the three phosphodiesterase-5 inhibitors sildenafil, vardenafil and tadalafil
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
A once-daily dose of tadalafil for erectile dysfunction: compliance and efficacy
ABO and rhesus blood group distribution in Kurds
Insomnia medication use and the probability of an accidental event in an older adult population
Detection of retinal changes in Parkinson's disease with spectral-domain optical coherence tomography
Safety aspects and rational use of a naproxen + esomeprazole combination in the treatment of rheumatoid disease
Solid self-nanoemulsifying cyclosporin A pellets prepared by fluid-bed coating: preparation, characterization and in vitro redispersibility
Erratum
  • Testimonials

    "You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio